Matrix Biology Institute

What Matrix Biology Institute does

Matrix Biology Institute (MBI) is a non-profit 501(c)(3) medical research organization headquartered at 17 Annett Avenue, Edgewater, New Jersey, dedicated to advancing the biological and medical knowledge of hyaluronan (hyaluronic acid), the polysaccharide that fills the intercellular space of the human body. The Institute was established in 1999 as the successor of an earlier entity co-founded in 1980 by Endre A. Balazs, M.D. — the pioneer who first purified hyaluronan for medical use in the 1930s–1940s — and Janet L. Denlinger, Ph.D., who currently serves as President. MBI conducts and supports hyaluronan research, publishes its findings (notably the five-volume "Hyaluronan: From Basic Science to Clinical Applications" book series and 40+ peer-reviewed publications, lectures, and book chapters), co-manages the International Society of Hyaluronan Sciences (ISHAS) and the Balazs Rooster Prize, and houses the historical archives of the Boston Biomedical Research Institute (BBRI).

The Institute's principal technology is the trademarked HylaSponge® System, a proprietary polymerization method that forms a network of large hyaluronan molecular chain-assemblies with virtually infinite molecular weight, marketed as a "second skin" for long-lasting hydration, wrinkle reduction, and delivery of biologically active ingredients such as vitamin C in cosmetic and skin-care applications. MBI's second core program is a pre-clinical hyaluronan joint-therapy research initiative, positioned as a more efficacious treatment for painful, mechanically damaged joints, with cooperative clinical-trial arrangements being developed with hospitals. The technology and research portfolio rests on biopolymer chemistry and decades of institutional hyaluronan expertise rather than on software, AI/ML, or digital platforms.

MBI's revenue model is a hybrid non-profit structure with three streams: (1) retail book sales of $20–$60 per title plus shipping via an Amazon.com storefront and direct PayPal checkout; (2) non-profit research grants and charitable funding consistent with its 501(c)(3) mission; and (3) intended or active B2B licensing of HylaSponge® technology to cosmetics and skin-care manufacturers (pricing not publicly disclosed). The Institute serves the global hyaluronan research community, prospective hospital clinical-trial partners, cosmetics manufacturers, and the general public. It operates with a lean team of approximately 3 named staff plus a 5–6 member Board of Trustees, and maintains a close executive relationship with the for-profit Hylaco, LLC, also based in Edgewater, NJ, where President Janet L. Denlinger serves as Chief Scientific Officer.

Name

Matrix Biology Institute

Legal name

Matrix Biology Institute

Website

https://matrixbio.org

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Matrix Biology Institute is a non-profit 501(c)(3) medical research organization in Edgewater, NJ, that advances hyaluronan science through research, scientific publishing, and the HylaSponge® skin-care technology, serving the global hyaluronan research community, hospitals, and cosmetics manufacturers.

Ownership category

akta.pro rank

Product category

Biomedical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYCRABAAAF

Dermocosmetics & Medical-Grade Skincare

Consumer Products & Retail/Beauty & Personal Care/Skincare

Keywords

• Hyaluronan research
• Biomedical research
• Skincare technology
• Scientific publications
• Non-profit research

Headquarters

HQ city

Edgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Book sales (Hyaluronan publications): One-time retail sales of hyaluronan-related books through Amazon.com storefront (Matrix Biology Institute's storefront) and PayPal checkout. Books priced $20-$60 plus shipping, plus a 5-volume set at $60 plus shipping.
2. Non-profit research grants and charitable funding: As a 501(c)(3) non-profit organization, MBI promotes and supports scientific research by granting funds for the conduct of such research, consistent with its mission to advance hyaluronan science.
3. HylaSponge® licensing to cosmetics/skin care industry: Commercialization of proprietary HylaSponge® skin-care technology for use in cosmetic and skin care products; the institute developed the technology through proprietary polymerization methods for industry use.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Matrix Biology Institute is a 501(c)(3) non-profit medical research organization that conducts and supports research on the biological function and medical use of hyaluronan (hyaluronic acid). Its primary commercial offering is the HylaSponge® System, a proprietary skin-care technology based on hyaluronan molecular chain-assemblies, which it develops and licenses to the cosmetics industry. The Institute also publishes the five-volume Hyaluronan book series and supports pre-clinical hyaluronan joint-therapy research.

Product overview

Matrix Biology Institute (MBI) is a non-profit, 501(c)(3) medical research organization based in Edgewater, New Jersey, whose principal product offering is the HylaSponge® System, a proprietary hyaluronan-based skin care technology developed from decades of hyaluronan research. This single commercial product is supported by the Institute's broader research and development activities, including pre-clinical hyaluronan joint therapy research and an extensive scientific publications program (notably the five-volume 'Hyaluronan: From Basic Science to Clinical Applications' book series and the MBI Publications catalog). The Institute also maintains the affiliated International Society of Hyaluronan Sciences (ISHAS), administers the Balazs Rooster Prize, organizes the international hyaluronan meetings series, and houses the historical archives of the Boston Biomedical Research Institute (BBRI).

Differentiator

Problem solved

Functional benefit

Brands

• HylaSponge®: The HylaSponge® System is a skin-care technology developed by Matrix Biology Institute, based on decades of research on hyaluronic acid (hyaluronan). It uses proprietary polymerization methods to create a network of large hyaluronan molecular chain-assemblies of virtually infinite molecular weight that absorb and release water and water-soluble molecules, acting as a long-lasting hydrating "second skin" for cosmetic and skin-care applications.

Products and services

• HylaSponge® System A proprietary skin care technology built on hyaluronan (hyaluronic acid) molecular chain-assemblies formed via proprietary polymerization methods. Acts as a 'second skin,' hydrating the stratum corneum, reducing the appearance of fine lines and wrinkles, and delivering water-soluble active ingredients such as vitamin C to deeper skin layers. Made available to cosmetic and skin care product manufacturers through licensing.
• Hyaluronan Book Series (Hyaluronan: From Basic Science to Clinical Applications) Five-volume scientific book series created and published by Matrix Biology Institute covering hyaluronan science, history, biology, and the structure and function of the biomatrix. Volumes 1 and 3 contain conversations with internationally recognized hyaluronan scientists; Volume 2 is a history of hyaluronan science; Volume 4 is the Tivadar Huzella memorial volume; and Volume 5 addresses the structure and function of the biomatrix. Sold individually (most at $20 plus shipping) or as a complete five-volume set ($60 plus shipping) via Amazon.com and PayPal.
• Hyaluronan Historical and Related Book Titles Additional hyaluronan-related books published and distributed by Matrix Biology Institute, including Hyaluronic Acid and Matrix Implantation (1971), Metabolism of Sodium Hyaluronate (1982), The Magic Molecule (2015), and Chemistry, Biology and Medical Applications of Hyaluronan, plus the 2-volume hardcover set Hyaluronan: Structure, Metabolism, Biological Activities, Therapeutic Applications. Sold via Amazon.com and PayPal at fixed unit prices plus shipping.

Quantifiable outcome

• HylaSponge® system reduces appearance of fine lines and wrinkles via intense hydration of the stratum corneum
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Amazon.comcoreChannel Partner/ Reseller/ DistributorAmazon.com hosts Matrix Biology Institute's storefront (amazon.com/shops/Matrixbiology) where MBI sells its hyaluronan books and related publications. Customers can purchase the full catalog of MBI-published books through this storefront.
• Endre A. Balazs FoundationminorGTM or Marketing PartnerThe Endre A. Balazs Foundation logo and link (endreabalazsfoundation.org) is displayed on MBI's homepage, indicating a cross-promotional/awareness relationship between the two non-profit entities associated with Endre A. Balazs' legacy.
• International Society of Hyaluronan Sciences (ISHAS)coreStrategic or Co-development PartnerISHAS was co-founded by Endre A. Balazs and Vincent C. Hascall in 2004 with 23 founding members from 7 countries. MBI's website hosts ISHAS content and co-manages the Balazs Rooster Prize awarded to scientists for significant hyaluronan contributions.
• Boston Biomedical Research Institute (BBRI)minorStrategic or Co-development PartnerBBRI was a related biomedical research organization whose annual reports (1980-2008), faculty book, 1970 brochure, 40th Anniversary booklet, and 2012 Boston Globe article on its closing are hosted on the MBI website. The relationship reflects historical institutional continuity with Endre A. Balazs and Janet L. Denlinger's research programs.
• Hylaco, LLCcoreStrategic or Co-development PartnerMBI President Janet L. Denlinger, Ph.D., also serves as Chief Scientific Officer of Hylaco, LLC (Edgewater, NJ), indicating a close executive and operational relationship between the two organizations at the leadership level.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Lifecore Biomedical: Lifecore is a CDMO and HA ingredient manufacturer supplying premium sodium hyaluronate for medical and skin-care applications — an emerging specialist competing with HylaSponge® at the ingredient layer.
• HTL Biotechnology: HTL Biotechnology is a specialist HA raw material supplier serving aesthetics and joint-therapy customers, overlapping with MBI's hyaluronan commercialization across both skincare and orthopedic applications.

Others

• Evonik Industries: Evonik supplies specialty HA and biopolymer ingredients into cosmetics and medical-device markets, positioning it as an enabling/supply-side peer adjacent to HylaSponge®'s skincare and dermatology customer base.
• Croda International: Croda supplies a broad portfolio of active and functional skincare ingredients including HA-based systems to global cosmetics brands, making it an enabling supplier peer competing indirectly for HylaSponge® licensing deals.

Direct peers

• Seikagaku Corporation: Seikagaku is a Japan-based HA-focused specialty pharmaceutical company with marketed joint (e.g., Supartz/Artz) and ophthalmic viscoelastic products, making it a directly comparable specialist competitor to MBI.
• Anika Therapeutics: Anika is a direct peer in HA-based intra-articular joint therapy (e.g., Monovisc, Orthovisc, Cingal), competing in the same orthopedic indication where MBI's pre-clinical joint program is being developed.
• Bioventus: Bioventus markets HA joint injectables such as Durolane and Supartz, making it a direct competitor in HA-based osteoarthritis pain therapy where MBI's pre-clinical joint product is positioned.

Broad incumbents

• AbbVie: AbbVie, via the Allergan acquisition, owns the Juvéderm HA dermal filler franchise and adjacent HA aesthetics products — overlapping with HylaSponge®-enabled skincare and active-ingredient delivery use cases.
• Galderma: Galderma (Nestlé-owned) markets Restylane, a major HA-based dermal filler brand (acquired via Q-Med), placing it as a broad incumbent competing with HylaSponge®-targeted skincare/aesthetics applications.
• Sanofi: Sanofi owns the Genzyme/Biomatrix hyaluronan heritage founded by MBI's founders, making it the dominant commercial incumbent in HA ophthalmic and intra-articular markets that MBI's joint-therapy program targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Matrix Biology Institute